首页> 美国卫生研究院文献>Genomics Society and Policy >Open consent biobanking and data protection law: can open consent be ‘informed’ under the forthcoming data protection regulation?
【2h】

Open consent biobanking and data protection law: can open consent be ‘informed’ under the forthcoming data protection regulation?

机译:公开同意书生物银行和数据保护法:根据即将出台的数据保护法规可以知情公开同意书吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This article focuses on whether a certain form of consent used by biobanks – open consent – is compatible with the Proposed Data Protection Regulation. In an open consent procedure, the biobank requests consent once from the data subject for all future research uses of genetic material and data. However, as biobanks process personal data, they must comply with data protection law. Data protection law is currently undergoing reform. The Proposed Data Protection Regulation is the culmination of this reform and, if voted into law, will constitute a new legal framework for biobanking. The Regulation puts strict conditions on consent – in particular relating to information which must be given to the data subject. It seems clear that open consent cannot meet these requirements. 4 categories of information cannot be provided with adequate specificity: purpose, recipient, possible third country transfers, data collected. However, whilst open consent cannot meet the formal requirements laid out by the Regulation, this is not to say that these requirements are substantially undebateable. Two arguments could be put forward suggesting the applicable consent requirements should be rethought. First, from policy documents regarding the drafting process, it seems that the informational requirements in the Regulation are so strict in order to protect the data subject from risks inherent in the use of the consent mechanism in a certain context – exemplified by the online context. There are substantial differences between this context and the biobanking context. Arguably, a consent transaction in the biobanking does not present the same type of risk to the data subject. If the risks are different, then perhaps there are also grounds for a reconsideration of consent requirements? Second, an argument can be made that the legislator drafted the Regulation based on certain assumptions as to the nature of ‘data’. The authors argue that these assumptions are difficult to apply to genetic data and accordingly a different approach to consent might be preferable. Such an approach might be more open consent friendly.
机译:本文着重于生物银行使用的某种形式的同意(公开同意)是否与提议的数据保护法规兼容。在开放式同意程序中,生物库一次向数据主体请求同意,以便将来对遗传物质和数据进行所有未来研究。但是,生物银行在处理个人数据时,必须遵守数据保护法。数据保护法目前正在改革中。拟议的《数据保护条例》是这项改革的高潮,如果被投票通过,它将构成生物银行的新法律框架。该法规对同意书规定了严格的条件,特别是与必须提供给数据主体的信息有关的条件。显然,公开同意不能满足这些要求。无法充分具体地提供4类信息:目的,接收者,可能的第三国转移,收集的数据。但是,尽管公开同意不能满足该法规提出的正式要求,但这并不是说这些要求基本上是不容置疑的。可以提出两个论点,建议应重新考虑适用的同意要求。首先,从有关起草过程的政策文件来看,该法规中的信息要求似乎是如此严格,以保护数据主体免受在某些情况下使用同意机制所固有的风险(例如在线环境)。在这种情况下与生物银行环境之间存在实质性差异。可以说,生物银行中的同意交易不会给数据主体带来相同类型的风险。如果风险不同,那么也许还有理由重新考虑同意要求吗?其次,可以说立法者基于某些关于“数据”性质的假设起草了该法规。作者认为,这些假设很难应用于遗传数据,因此,不同的同意方法可能更可取。这样的方法可能会更开放友好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号